Regeneron's BCMAxCD3 Bispecific Antibody (REGN5458) Shows Deep and Durable Responses in Patients with Heavily-pretreated Multiple Myeloma in Phase 1

TARRYTOWN, N.Y., Dec. 5, 2020 /PRNewswire/ -- 63% response rate in patients treated with the highest reported dose Among all patients responding to treatment, 95% experienced a very good partial response or better; among responding patients with ≥6 months of follow-up, 83% have ongoing...

from PR Newswire: https://ift.tt/3oqpAxD